On the Record · DR Reddys Laboratories
DR Reddys Laboratories acquisitions, on the record
The businesses DR Reddys Laboratories bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.
Deals its annual reports describe
| Business | Deal | When | Value |
|---|---|---|---|
U.S. generic prescription products portfolio from Mayne Pharma Group LimitedWord for word“Chargebacks provisions and payments for the year ended March 31, 2024 were each higher as compared to the year ended March 31, 2023, primarily as a result of the Company’s acquisition of a U.S. generic prescription products portfolio from Mayne Pharma Group Limited in April 2023, higher sales volumes and also due to higher pricing rates per unit for chargebacks.” 20-F for 2024 | acquisition | April 2023 | — |
Territorial rights to Ciprolet and Levolet brands in Russia and certain countries of the former Soviet Union (Alium JSC)Word for word“An agreement with Alium JSC for the sale of the Company’s territorial rights relating to two of its anti-bacterial brands (Ciprolet® and Levolet®) in Russia and certain countries of the former Soviet Union.” 20-F for 2024 | agreed divestiture | — | — |
MenoLabs product portfolio from Amyris, Inc.Word for word“In January 2024, we acquired from Amyris the MenoLabs ® products portfolio from, a leading women’s health and dietary supplement branded portfolio, for aggregate consideration of Rs.228 million (U.S.$3 million).” 20-F for 2024 | acquisition | January 2024 | Rs.228 million (U.S.$3 million) |
Nimbus Health GmbHWord for word“The acquisition of Nimbus Health GmbH (“Nimbus Health”) in February 2022 marked our entry into the medical cannabis sector.” 20-F for 2024 | acquisition | February 2022 | — |
Premama maternity wellness brand from Luna Pharmaceuticals, Inc.Word for word“We also started renovating our existing brands of Doan’s ® and Habitrol ® and re-launch the maternity wellness brand Premama®, that was acquired from Luna Pharmaceuticals, Inc. back in Jan 2023.” 20-F for 2024 | acquisition | Jan 2023 | — |
A unit of The Dow Chemical Company (Mirfield site)Word for word“As a result of the acquisition of a unit of The Dow Chemical Company in April 2008, the Company assumed a liability for contamination of the Mirfield site acquired of Rs.39 (carrying value Rs.61).” 20-F for 2024 | acquisition | April 2008 | — |
Non-core brands in India (Global Generics segment)Word for word“This decline in revenues was largely attributable to the divestment of a few non-core brands in the year ended March 31, 2023, partially offset by an increase in sales prices and volumes of certain of our existing products and revenues from launches of new products .” 20-F for 2024 | divestiture | year ended March 31, 2023 | — |
Cheminor Drugs LimitedWord for word“He was the Managing Director of Cheminor Drugs Limited prior to its merger with Dr. Reddy’s Laboratories.” 20-F for 2024 | merger | — | — |
a unit of The Dow Chemical CompanyWord for word“As a result of the acquisition of a unit of The Dow Chemical Company in April 2008, the Company assumed a liability for contamination of the Mirfield site acquired of Rs.39 (carrying value Rs.64).” 20-F for 2026 | acquisition | April 2008 | — |
Read from DR Reddys Laboratories’s annual reports (20-F for 2026, 20-F for 2025, 20-F for 2024) and the financial data it files with the SEC, as of 2026-05-29. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.